Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors
Abstract
PCSK9 gene-editing is considered a potential one-time approach, though safety and durability concerns remain unresolved. Implementation remains rate-limiting. Costs, prior authorization, variable coverage, distribution, injection logistics, and adherence barriers delay initiation and erode persistence. Uninsured patients may face prohibitive out-of-pocket expenses without assistance pathways.
Fields of Study & Subjects
Lipoproteins and Cardiovascular Health
Cancer
Lipids
and Metabolism
Cholesterol and Lipid Metabolism
Publication details
- Journal / source
- Journal of Clinical Medicine Research
- Publisher
- Elmer Press, Inc.
- Volume
- 18
- Issue
- 3
- Pages
- 121–141
- Publication date
- 1 March 2026
- Language
- EN